The personalized mRNA vaccine, developed in collaboration between Moderna and Merck, has achieved a significant breakthrough in the treatment of melanoma, as it helps the immune system recognize cancer cells after surgery and reduces the risk of disease recurrence, as demonstrated by a successfully completed phase three clinical trial. (translated)





